Histories: Ceremony, Canadian Psychiatry, Prohibition and Revival
Psychedelic-Assisted Medicine: Science and Practice
Learning objectives for this lesson:
- Describe the peyote, Mazatec mushroom, Amazonian ayahuasca and Bwiti iboga traditions, drawing on Indigenous-authored sources where they exist.
- Explain how religious and state authorities suppressed ceremonial traditions and how outside attention, such as Wasson's 1957 article, harmed communities including María Sabina's, and apply four questions to judge outside accounts of ceremony.
- Describe the work of Humphry Osmond and Abram Hoffer in Saskatchewan, including the proposal of the word "psychedelic" in 1956 and its public introduction in 1957, and LSD treatment of alcohol use disorder.
- Compare the psycholytic and psychedelic models of therapy and describe LSD treatment at Hollywood Hospital in New Westminster using archival evidence.
- Calculate and interpret risks, risk differences and odds ratios from the pooled randomized trials of LSD for alcohol use disorder.
- Describe MKUltra and Ewen Cameron's depatterning at the Allan Memorial Institute, apply the Nuremberg Code to them, and summarize Canada's responses from the Cooper report of 1986 to 2026.
- Explain how drug regulation in 1962, criminalization and the 1971 Convention on Psychotropic Substances ended the first research era, including the reservations for peyote.
- Trace the revival from MDMA's scheduling and the founding of MAPS and the Heffter Research Institute to Griffiths et al. (2006), and explain the lessons of the Good Friday follow-up and the Ricaurte retraction.
- Describe how legal access reopened in Canada through the 2017 ayahuasca church exemptions, the 2020 psilocybin exemptions supported by TheraPsil and the 2022 Special Access Program amendments.
- Place Canadian and international events from ancient times to 2022 in sequence and identify the lessons for practice that the course draws from this history.
This course was developed by Dr. Kiffer G. Card.
Indigenous and Ceremonial Traditions, Colonial Suppression and the Harms of Outside Attention
Content note
This section discusses the colonial suppression of Indigenous ceremonies and harms to Indigenous communities, including the repeated burning of a healer's home. If you would like support, the Hope for Wellness Help Line for Indigenous people is available at 1-855-242-3310, and the 9-8-8 Suicide Crisis Helpline can be reached by call or text at 9-8-8.
Introduction
Lesson 1 defined the substances that this course studies and set out a checklist for weighing claims about them. This lesson turns to their histories, because the present field inherits practices, institutions, laws and harms from earlier periods. Section 1 begins long before clinical research, with ceremonial traditions in which Indigenous peoples have used peyote, psilocybin mushrooms, ayahuasca and iboga; the later sections follow mid-century psychiatry, coercion and prohibition, and the revival.
A history of ceremonial traditions raises the question of whose knowledge is described and for whom, because many published accounts were written by outsiders, and some caused harm. An Indigenous-led consensus group has described "increasing concerns from many Indigenous Nations regarding cultural appropriation, lack of recognition of the sacred cultural positioning of these medicines, exclusionary practices in research and praxis, and patenting of traditional medicines" (Celidwen et al., 2023). The box below explains how this section responds to those concerns.
How this lesson describes ceremonial traditions
This section reports what published sources, including Indigenous-authored sources where they exist, say about the history and legal status of each tradition. It describes ceremonies only as far as communities and their scholars have made them public, and it does not present them as techniques or resources for outsiders to adopt. Terms such as "Spirit medicines," which Celidwen et al. (2023) use, appear only when describing how communities name their own practices. Indigenous peoples appear here as holders of knowledge and rights, and the harms described are harms done to them.
Learning Objectives
- 1.1 Describe the ceremonial use of peyote in the Native American Church, of psilocybin mushrooms in Mazatec veladas, of ayahuasca in Amazonian and Brazilian traditions, and of iboga in Bwiti.
- 2.1 Explain how religious and state authorities suppressed these traditions, from the condemnation of peyote by 1620 to Canada's ban on the potlatch from 1884 to 1951.
- 2.2 Describe the harms that followed outside attention to María Sabina's community in Huautla de Jiménez after 1955.
- 2.3 Identify the harms that Indigenous organizations attribute to tourism, overharvesting and commercialization, and the protections they have sought.
- 2.4 Apply four questions to judge any written account of a ceremonial tradition, including who is speaking and who benefits.
1.1 Four Ceremonial Traditions
The four traditions in this section differ in plant, region, ceremony and legal history, and each predates clinical research by centuries. Table 2.1 summarizes them before the subsections describe each one; a single row cannot capture the variation within a tradition.
Table 2.1. Four ceremonial traditions compared by plant, people and region, suppression or recognition, and the effects of outside attention (sources are cited in the subsections that follow).
| Tradition | Plant and main compound | Peoples and region | Suppression or recognition | Effects of outside attention |
|---|---|---|---|---|
| Peyote meetings of the Native American Church | Peyote cactus (Lophophora williamsii); mescaline | Indigenous Nations of the southern plains, then across the United States and into Canada | Condemned by the Spanish Inquisition and the Catholic Church by 1620; protected in United States law since 1994 | Scarcity of wild peyote; church leaders ask decriminalization campaigns not to name it |
| Mazatec mushroom ceremonies (veladas) | Psilocybe mushrooms; psilocybin and psilocin | Mazatec people of the Sierra Mazateca, Oaxaca, Mexico | Recorded by a colonial chronicler; in the 1960s, authorities expelled visitors and blamed a healer | Tourism after 1957; a healer's house burned on several occasions |
| Ayahuasca ceremonies | Banisteriopsis caapi vine with Psychotria viridis leaves; DMT with beta-carbolines | Indigenous peoples of the Amazon; mestizo healers; Brazilian churches since the early 1930s | Peru declared traditional knowledge and use national cultural heritage in 2008 | Growing ceremonial tourism by non-Indigenous visitors |
| Bwiti initiation | Iboga shrub (Tabernanthe iboga) root bark; ibogaine | Bwiti practitioners in Gabon and Equatorial Guinea | Missionary and colonial persecution, 1930 to 1950; declared a strategic heritage reserve in Gabon in 2000 | Western demand for ibogaine; overharvesting and poaching |
1.1.1 Peyote and the Native American Church
Peyote is a small, spineless cactus whose main psychoactive compound is mescaline, which Lesson 3 describes pharmacologically. Archaeological evidence from a small number of dated specimens suggests that its use is very old. El-Seedi et al. (2005) radiocarbon dated two peyote buttons, presumed to come from Shumla Cave No. 5 on the Rio Grande in Texas, to about 3780 to 3660 BCE, identified mescaline in both, and concluded that the finding "strengthens the evidence that native North Americans recognized the psychotropic properties of peyote as long as 5700 years ago."
Opposition to peyote is also old. Littlefish (2005) dates it to at least 1620, when the Spanish Inquisition and the Catholic Church condemned peyote use. The modern peyote religion took shape on reservations in southwestern Indian Territory, now Oklahoma, in the 1870s, and by Oklahoma statehood in 1907 it had spread to most Oklahoma tribes (Swan, 2010). Swan names Quanah Parker (Comanche) as the figure most closely associated with its early history. On 10 October 1918, an intertribal coalition incorporated the Native American Church of Oklahoma, which gave the religion a legal identity at a time when peyotists faced "numerous organized efforts" to prevent their use of peyote (Swan, 2010). Services, called meetings, are usually held overnight in a tipi, led by respected members called roadmen, with singing, prayer and peyote taken as a sacrament (Swan, 2010).
The church also reached Canada. Littlefish (2005) reports that Cree, Assiniboine, Ojibwa and Blood members formed the Native American Church of Canada at Red Pheasant, Saskatchewan, in 1954. In 1956, the psychiatrists Abram Hoffer and Humphry Osmond, whose clinical work Section 2 describes, joined members of the Red Pheasant First Nation near North Battleford at a peyote ceremony hosted by the Native American Church of Canada, and afterward wrote essays defending peyote use (Kahan, 2016). The book's publisher describes its analysis as dated and sometimes uncritical, a reminder that sympathetic outsiders also wrote from their own positions (Kahan, 2016).
Legal protection came late. After the Supreme Court of the United States held in Employment Division v. Smith (1990) that the First Amendment does not protect Indian practitioners who use peyote in religious ceremonies, Congress enacted the American Indian Religious Freedom Act Amendments on 6 October 1994, which provide that the use, possession or transportation of peyote by an Indian "for bona fide traditional ceremonial purposes in connection with the practice of a traditional Indian religion is lawful" (42 U.S.C. § 1996a). In Canada, as of October 2026, the Controlled Drugs and Substances Act lists mescaline in Schedule III "but not peyote (lophophora)," and Section 3 explains the reservation for peyote that Canada made when it joined the 1971 Convention on Psychotropic Substances.
1.1.2 Mazatec Mushroom Ceremonies and María Sabina
In the Sierra Mazateca of Oaxaca, Mexico, Mazatec healers have long used psilocybin-containing mushrooms in night-time ceremonies called veladas. An early colonial chronicler, the Franciscan friar Bernardino de Sahagún, had described an inebriating mushroom that Nahuatl speakers called teonanacatl, "the flesh of gods," and Mexican scientists sought to identify it from the late nineteenth century (Garcia de Teresa, 2022).
R. Gordon Wasson, a J.P. Morgan vice-president who studied fungi in human cultures with his wife, Valentina Pavlovna Wasson, first visited Huautla de Jiménez in August 1953 (Garcia de Teresa, 2022). On 29 June 1955, Wasson and his companion Allan Richardson took part in a velada led by the curandera (healer) María Sabina. Wasson paid her 50 pesos, about US$4, and his hosts refused a gift of 100 pesos, saying, "we did not do this for money" (Garcia de Teresa, 2022, citing Wasson and Pavlovna, 1957). In 1957, Wasson published an account of the ceremony, "Seeking the Magic Mushroom," in Life magazine. He had told his main local intermediary that he had changed the names of people and places to avoid disturbing them (Garcia de Teresa, 2022). Early in 1958, a team at the Sandoz company in Switzerland led by Albert Hofmann isolated psilocybin from the mushrooms (Hofmann et al., 1958), and in 1962 Wasson and Hofmann held a velada at María Sabina's house using psilocybin pills (Garcia de Teresa, 2022). Case 2.1, later in this section, describes the consequences for Huautla.
1.1.3 Amazonian Ayahuasca Traditions
Ayahuasca is a decoction made from the bark of the Banisteriopsis caapi vine, which contains beta-carboline alkaloids, and the leaves of the Psychotria viridis shrub, which supply N,N-dimethyltryptamine (DMT) (Hamill et al., 2019). Lesson 3 explains why the combination matters pharmacologically. Hamill et al. (2019) describe its original use by Indigenous healers in several South American countries for spirit communication, healing and religious ritual, its later spread into mestizo folk medicine in Peru, Colombia and Ecuador, and its adoption as a sacrament, beginning in the early 1930s, by three Brazilian churches that combine Indigenous and Christian traditions: the Santo Daime, which Hamill et al. describe as the oldest, the União do Vegetal and the Barquinha.
In 2008, Peru's National Institute of Culture declared the traditional knowledge and uses of ayahuasca practised by native Amazonian communities part of the Cultural Heritage of the Nation, in Resolución Directoral Nacional No. 836/INC. The resolution aimed to protect the ritual's traditional use and sacred character and to distinguish it from decontextualized, consumerist Western uses (Andina, 2008). The Brazilian churches carried the brew abroad, and Section 4 describes how two of them obtained exemptions in Canada in 2017.
1.1.4 Bwiti and Iboga
Iboga (Tabernanthe iboga) is a Central African shrub whose root bark contains ibogaine, an alkaloid whose pharmacology, cardiac risks and study in opioid use disorder appear in Lessons 3, 6 and 10. In Gabon, the root is central to Bwiti, a religion whose initiation rites have used it for centuries (Bonhomme, 2023). The anthropologist Julien Bonhomme (2023) traces how Western researchers identified the plant in the 1890s, how it was sold in France from the 1930s as a tonic called Lambarène, and how ibogaine gained a Western reputation in the 1960s as a drug said to end addiction.
Bwiti itself was persecuted. Samorini (2025) describes "missionary and colonial persecutions" of the Bwiti religion in Gabon and Equatorial Guinea between 1930 and 1950. After independence, the Gabonese state took a different position, and in 2000 its Council of Ministers declared Tabernanthe iboga a "cultural heritage strategic reserve" (Ermakova, 2021).
2.1 Colonial Suppression
Each of these traditions drew the attention of outside authorities, and their records share a pattern in which religious and state institutions treated ceremonial use as a threat. This part summarizes that pattern and connects it to Canada; HSCI 214 develops the history and health effects of colonialism.
Religious authorities often acted first, as with the Inquisition's condemnation of peyote and the missionary persecution of Bwiti, and state authorities followed with law, as in the long campaign against peyote in the United States that ended only with the protection of 1994 (Littlefish, 2005; Samorini, 2025; Swan, 2010).
Canada's record of suppressing Indigenous ceremony concerned other ceremonies, and it forms the setting in which the Native American Church of Canada was founded. An 1884 amendment to the Indian Act banned the potlatch as part of a policy of assimilation, and the ban was removed only in 1951 (Gadacz, 2006). The founding of the Native American Church of Canada at Red Pheasant in 1954 therefore came three years after that ban ended. Figure 2.1 places these events in a sequence that recurs across the cases in this section.
The order of the steps in Figure 2.1 varies: suppression of peyote came long before publicity, while the most visible harms to the Mazatec ceremonies followed it. The next part examines that second kind of harm.
2.2 Harms That Followed Outside Attention in Huautla de Jiménez
Outside attention brought new harms to communities whose practices had survived suppression. This part examines Huautla de Jiménez after 1957, and the next part turns to two harms that Indigenous organizations identify today: pressure on scarce plants and the commercialization of ceremony.
Case 2.1 draws on Marcos Garcia de Teresa's (2022) historical and ethnographic study of the mushroom trade in the Sierra Mazateca, based on Wasson's archived diaries and letters and on Mexican newspapers.
After the Life article of 1957, visitors began to arrive in Huautla in search of the mushrooms, and Wasson's own purchases grew: in 1958 he bought about 125 kilograms of mushrooms through local intermediaries. María Sabina's fees rose from 50 pesos in 1955 to 150 pesos for a ceremony for Wasson in 1959. Around 1960 she held ceremonies at a hotel, for which she charged 400 pesos, and by 1960 a tour company was selling a "Safari" that included two nights in Huautla. Government officials and conservative sectors of the community held María Sabina responsible for incidents involving foreigners under the influence of the mushrooms, and her house was burned down on several occasions. In September 1967, at the request of local authorities and under pressure from the press, the federal Ministry of the Interior deported thirty-two Americans from the town, and in July 1969 the Attorney General's Office requested soldiers in helicopters to evict visitors whom a newspaper described as "two thousand hippies." In 1970, Wasson wrote in The New York Times that he had nightmares about the commercial exploitation he had set loose. The Mazatec journalist Álvaro Estrada, María Sabina's biographer, described the arrival of foreign mushroom consumers as a "profanation" of the mushroom spirit (Garcia de Teresa, 2022).
In Case 2.1, publicity created demand, demand turned a ceremony into a commodity, and the state's response fell on visitors and on the healer who had received them. Garcia de Teresa (2022) cautions against a simple story of a pure tradition corrupted by money: Mazatec healers had long received payment in goods or cash, tourism now provides a modest income for some families, and the objection that Rodríguez Venegas (2017) records is to clients being deceived "with excessive fees and false promises" (cited in Garcia de Teresa, 2022). Outside attention left costs and benefits distributed unevenly within the community.
2.3 Scarce Plants, Tourism and Commercialization
Beyond Huautla, outside demand has put pressure on the plants themselves and turned some ceremonies into products for visitors.
2.3.1 Pressure on Scarce Plants
Peyote grows naturally in the United States only in a small area of southern Texas, and that limited habitat is a major cause of the current shortage, according to a statement issued on 30 March 2020 by the National Council of Native American Churches and the board of the Indigenous Peyote Conservation Initiative (NCNAC & IPCI, 2020). The statement asked that decriminalization resolutions not name peyote and that non-Native people look for alternatives that do not harm the peyote population, warning that naming peyote could create a "false sense of legality" and increase illegal harvesting.
Iboga faces similar pressure. Ermakova (2021) reports that overharvesting and poaching continue despite Gabon's legal protections, and that the effect of harvesting and export on Bwiti practitioners receives little attention.
2.3.2 Tourism, Commercialization and the Indigenous Critique
By 2019, ayahuasca was drawing a growing number of non-Indigenous visitors to the Amazon for ceremonies led by local healers, which the research literature calls spiritual or shamanic tourism (Hamill et al., 2019). Celidwen et al. (2023) report the consensus of an Indigenous-led, globally represented group of practitioners, activists, scholars, lawyers and human rights defenders, which concluded that the continuing extraction and commercialization of traditional Indigenous medicines by Western institutions harms Indigenous life in four ways: the glorification of psychedelics encourages "spiritual consumerism" and exploitative tourism that is often managed by Westerners; unsustainable foraging makes the medicines increasingly unavailable for local use; drug cartels bring violence into traditional territories; and false information spreads that a particular plant medicine is the key to human enlightenment.
The same group identified eight interconnected ethical principles for Western research and practice: reverence, respect, responsibility, relevance, regulation, reparation, restoration and reconciliation (Celidwen et al., 2023). Lesson 12 examines these principles and benefit sharing under the Nagoya Protocol. The accordion that follows lists the main responses described in this lesson, in date order.
Canada acceded to the 1971 Convention on Psychotropic Substances on 10 September 1988 with a reservation for peyote, which Section 3 discusses (United Nations Treaty Collection, 2026).
The 1994 amendments made ceremonial peyote use by Indians lawful throughout the United States (42 U.S.C. § 1996a).
Gabon's Council of Ministers declared Tabernanthe iboga a "cultural heritage strategic reserve" (Ermakova, 2021).
Peru's National Institute of Culture declared the traditional knowledge and uses of ayahuasca by native Amazonian communities part of the Cultural Heritage of the Nation (Andina, 2008).
Native American Church organizations asked decriminalization campaigns to leave peyote out of their resolutions (NCNAC & IPCI, 2020).
Celidwen et al. (2023) set out eight principles to guide Western psychedelic research and practice in its relations with traditional Indigenous medicines.
These responses come from states, churches and Indigenous-led groups, and they protect ceremonial use, plants, knowledge and relationships. The final part of this section turns to the accounts through which outsiders learned about the traditions.
2.4 Reading Accounts of Ceremonial Traditions
Most of what people outside these communities learn about ceremonial traditions comes from accounts by outsiders, whose quality and ethics vary. The four flip cards below give questions to ask of any such account, and Try it 2.1 applies them to Wasson's article.
Using only the facts in this section and Case 2.1, write one sentence answering each of the four questions on the flip cards for Wasson's 1957 article in Life. Then name the harm, among the four identified by Celidwen et al. (2023), that Case 2.1 illustrates most clearly, with one supporting fact. A strong answer notes that the hosts said they "did not do this for money" and that the costs fell on María Sabina and her community.
Summary
Peyote, psilocybin mushrooms, ayahuasca and iboga were used in religious and healing ceremonies long before clinical research began. Religious and state authorities condemned or persecuted several of these traditions, and Canada's ban on the potlatch from 1884 to 1951 belongs to the same colonial pattern. Outside attention, such as Wasson's 1957 article, brought tourism, commercialization, state violence and pressure on scarce plants, and Indigenous organizations have responded with statements and ethical principles.
The decade that brought visitors to Huautla also brought two Saskatchewan psychiatrists, already giving LSD to patients, to a peyote ceremony at Red Pheasant. Section 2 follows their work and the treatment offered at Hollywood Hospital in New Westminster.
Key Takeaways
- 1.1 Peyote, psilocybin mushrooms, ayahuasca and iboga were used in religious and healing ceremonies long before clinical research began, and peyote specimens containing mescaline from a Texas rock shelter date to about 5,700 years ago. The Native American Church, incorporated in Oklahoma in 1918 and formed in Canada at Red Pheasant in 1954, takes peyote as a sacrament in overnight meetings; Mazatec healers such as María Sabina lead night-time mushroom veladas; ayahuasca passed from Indigenous Amazonian healers to Brazilian churches from the early 1930s; and Bwiti initiation in Gabon uses iboga root bark.
- 2.1 Religious authorities often acted first, as with the condemnation of peyote by 1620 and the missionary persecution of Bwiti from 1930 to 1950, and states followed with law, so that ceremonial peyote use gained federal protection in the United States only in 1994. Canada's ban on the potlatch from 1884 to 1951 belongs to the same colonial pattern, and Figure 2.1 shows a recurring sequence from community practice through outside documentation and demand to harms and responses.
- 2.2 After Wasson's 1957 article in Life, visitors and buyers came to Huautla de Jiménez, the mushroom trade and María Sabina's fees grew, officials and conservative sectors of the community blamed her for incidents involving foreigners, and her house was burned on several occasions. Federal authorities deported and evicted visitors in 1967 and 1969. Garcia de Teresa (2022) cautions that payment was not new to Mazatec healing and that the costs and benefits of outside attention fell unevenly within the community.
- 2.3 Limited habitat has made peyote scarce, and Native American Church organizations asked in 2020 that decriminalization campaigns not name it, while iboga faces overharvesting and poaching despite Gabon's protections. An Indigenous-led consensus (Celidwen et al., 2023) named four harms of extraction and commercialization (spiritual consumerism and exploitative tourism, unsustainable foraging, cartel violence and false information) and set out eight ethical principles. Protections also include Gabon's 2000 declaration for iboga and Peru's 2008 heritage declaration for ayahuasca.
- 2.4 Any written account of a ceremonial tradition can be judged by four questions: who is speaking and from what position, whether the community consented to publication, what kind of evidence the account offers, and who benefits and who bears the costs. Applied to Wasson's 1957 article, the questions reveal an outsider writing for a mass-circulation magazine, changed names that did not protect the place, one visitor's impressions offered as evidence, and costs that fell on María Sabina and her community.
Reflection
On 29 June 1955, the banker R. Gordon Wasson took part in a Mazatec mushroom ceremony (a velada) in Huautla de Jiménez, Mexico, led by the curandera María Sabina. He paid her 50 pesos, and his hosts refused a further gift, saying "we did not do this for money." In 1957 he published an account in Life magazine, changing the names of people and places. Visitors followed; officials and conservative sectors of the community blamed María Sabina for incidents involving foreigners, her house was burned on several occasions, and in 1967 and 1969 the authorities deported and evicted visitors. Imagine that you are a researcher today who has been invited to observe a ceremony in a community whose practice has never been publicly described. Using the four questions from Section 1 (who is speaking, whether the community consented to publication, what kind of evidence the account offers, and who benefits and bears the costs) and at least two of the eight principles named by Celidwen et al. (2023) (reverence, respect, responsibility, relevance, regulation, reparation, restoration and reconciliation), explain in 120 to 250 words what you would do differently from Wasson and why.
Minimum 20 characters required.
Question 1: What did El-Seedi et al. (2005) find when they analyzed two peyote specimens from Shumla Cave No. 5 in Texas?
Question 2: Which development followed the publication of Wasson's article in Life in 1957?
Question 3: What did the 2020 statement by the National Council of Native American Churches and the Indigenous Peyote Conservation Initiative ask of decriminalization campaigns?
Question 4: Which statement about Canada is supported by Section 1?
Mid-Century Psychiatry in Canada: Weyburn, Hollywood Hospital and Two Models of Therapy
Introduction
Section 1 ended with two Saskatchewan psychiatrists at a peyote ceremony in 1956. This section follows their clinical work and the wider mid-century effort to use LSD in psychiatry. Albert Hofmann, a chemist at the Sandoz company in Basel, discovered the effects of LSD in 1943, and in the following fifteen years more than a thousand articles on its use appeared (Dyck, 2015). Canada was a centre of this work, at Weyburn and at Hollywood Hospital in New Westminster. The sources of the period use terms that this course otherwise avoids, and the box below explains how the section handles them.
Historical terms and the language of this course
Mid-century researchers wrote of "alcoholism" and "alcoholics" and described LSD as "psychotomimetic" (psychosis-mimicking). This section keeps such words inside quotations and titles and otherwise uses the course's terms, such as "alcohol use disorder" and "session." The historical trials also predate today's diagnostic criteria: the first edition of the Diagnostic and Statistical Manual (1952) defined alcoholism as a "well established addiction to alcohol without recognizable underlying disorder" (Krebs & Johansen, 2012).
Learning Objectives
- 3.1 Describe the work of Humphry Osmond and Abram Hoffer in Saskatchewan in the 1950s, including the model-psychosis approach and the word "psychedelic," proposed in 1956 and introduced publicly in 1957.
- 3.2 Explain the rationale for single-session LSD treatment of alcohol use disorder and why Toronto's Alcoholism and Drug Addiction Research Foundation disputed the Saskatchewan results.
- 4.1 Describe LSD treatment at Hollywood Hospital in New Westminster, distinguishing archival evidence from later popular accounts.
- 4.2 Compare the psycholytic and psychedelic models of therapy by dose, number of sessions, theory and goal.
- 5.1 Calculate risks, a risk difference and an odds ratio from the pooled counts reported by Krebs and Johansen (2012), and explain why they differ from the meta-analytic estimates.
3.1 Osmond and Hoffer in Saskatchewan
The Saskatchewan research grew out of a particular provincial setting and theory of mental illness. This part describes both and the coining of the word "psychedelic," and the next part turns to the treatment of alcohol use disorder.
In 1944, Saskatchewan elected the first socialist government in North America, led by Premier Tommy Douglas, which over the next seventeen years built the framework for a medicare program (Dyck, 2019). Humphry Osmond, a British psychiatrist, arrived in the province in 1951 and became clinical director, and later superintendent, of the Saskatchewan Mental Hospital in Weyburn, one of the largest asylums in North America. Abram Hoffer, a Saskatchewan-born psychiatrist and biochemist, was a researcher with the Psychiatric Services Branch of the provincial health department, and the two met soon after Osmond's arrival (Dyck, 2019). The historian Erika Dyck (2005) describes their studies, led by Osmond in Weyburn and Hoffer in Saskatoon, as "some of the most widespread trials in the Western world."
Osmond and Hoffer were first drawn to LSD and mescaline because the drugs seemed to produce a "model psychosis," a temporary state resembling schizophrenia (Dyck, 2005). Osmond proposed that staff who took LSD could better understand their patients, and the two researchers argued that a true psychosis might reflect a chemical imbalance, which led them to promote a biochemical account of schizophrenia (Dyck, 2005, 2019). The work also produced reforms in hospital design and in training psychiatric nurses to offer comfort and empathetic care (Dyck, 2019).
In March 1953, Osmond received a letter from the novelist Aldous Huxley and then flew to Los Angeles to meet Huxley and his wife, Maria, bringing mescaline (Dyck, 2019); Osmond supervised Huxley's mescaline session on 5 May 1953 (Costandi, 2014). At the time, researchers often described these drugs as "psychotomimetic" (Mangini, 1998), a term that named only one aspect of their effects. Osmond first proposed the word "psychedelic," usually glossed as "mind-manifesting," in 1956 (Kelmendi et al., 2022), in correspondence with Huxley: in reply to a rhyme by Huxley, he wrote, "To fathom Hell or go angelic / Just take a pinch of PSYCHEDELIC" (quoted in Dyck, 2019). He introduced the word publicly in a medical paper in 1957 (Dyck, 2019; Costandi, 2014). The new word marked a shift from treating the drugs as tools for imitating illness to treating them as agents that might reveal and change the mind.
3.2 LSD and Alcohol Use Disorder
The best-known Saskatchewan work concerned alcohol use disorder. Early researchers had observed that the frightening experience of delirium tremens, a severe form of alcohol withdrawal, sometimes led people to moderate their drinking, and they reasoned that the experience they believed LSD produced might have a similar effect (Mangini, 1998). Dyck (2019) describes the aim as giving LSD before a person reached "rock bottom," which might spare them liver damage and the criminal or aggressive behaviour that could accompany years of heavy drinking. Osmond and Hoffer began giving LSD to patients with alcohol use disorder in 1953 (Costandi, 2014).
The first Saskatchewan trials reported unusually high rates of abstinence (Dyck, 2006), and studies that followed patients for up to two years reported recovery rates of 50 to 90 percent (Dyck, 2019). Provincial authorities, local Alcoholics Anonymous groups and the Bureau of Alcoholism supported the treatment and a public campaign for it. Toronto's Alcoholism and Drug Addiction Research Foundation, which Dyck (2006) calls Canada's leading addiction authority, disputed the Saskatchewan results and asked the advocates to run controlled trials. That dispute set the terms on which the treatment would be judged.
4.1 Hollywood Hospital in New Westminster
Saskatchewan's public research had a private counterpart in British Columbia. This part describes what the archival record shows about Hollywood Hospital and compares it with later popular accounts, because the two kinds of source report different figures.
The hospital was founded in New Westminster in 1919 as the Hollywood Sanitarium, a private facility for people with alcohol and other addictions, and it took the name Hollywood Hospital in 1959 (Royal BC Museum, 2013). In 1957, its medical director, J. Ross MacLean, began using LSD and related drugs to treat alcohol use disorder and various personality disorders. He and his colleagues reported good results, the provincial government and the wider medical community viewed the treatments with suspicion, and by 1975 MacLean had been pressured into closing the hospital (Royal BC Museum, 2013). The journalist Jesse Donaldson (2019) adds that MacLean bought the 55-bed hospital in 1956, that Al Hubbard, an American promoter of LSD whose credentials Donaldson reports had been purchased, joined him in 1957, and that fees ran from 600 to 1,000 dollars on a sliding scale. A review of Donaldson and Dyck's later book describes Hubbard's credentials as "suspect" and credits him as one architect of a "Canadian psychedelic therapy method" (Marquis, 2023).
Table 2.2 sets the archival description beside the popular account, which explains why the dates and numbers attached to the hospital vary between sources.
Table 2.2. What an archival description and a popular account report about LSD treatment at Hollywood Hospital.
| Question | BC Archives, Hollywood Hospital fonds (Royal BC Museum, n.d.) | Magazine account (Donaldson, 2019) |
|---|---|---|
| When did LSD treatment take place? | LSD treatment began in 1957; the 510 surviving case files of patients treated with these drugs have opening dates from 1957 to 1968, with some later files for returning patients; the hospital closed by 1975 | Supervised LSD sessions ran from 1957 to 1975 |
| How many people were treated? | Index cards indicate that more than 800 patients received the treatment; only about two-thirds of their files have been located | More than 6,000 supervised sessions |
| What were the outcomes? | MacLean and colleagues "reported good results"; the records do not give outcome rates | A reported success rate of 50 to 80 percent |
| What kind of evidence is this? | A description of patient records held by a public archive, with access restricted | Journalism drawing on newspapers, interviews and the hospital's own claims |
The two sources count different things: the archive counts patients and files, the magazine counts sessions, and a patient could have several sessions. The success rate is the clinic's own claim, without a comparison group. This lesson therefore dates the documented LSD treatment to case files opened between 1957 and 1968 and the closure to 1975, and treats the session count and success rate as reported claims. Lesson 5 returns to Hollywood Hospital in its history of set and setting.
4.2 Two Models of Therapy
Mid-century clinicians used LSD in two broad ways, and the difference still shapes how trials are designed. This part describes the two models, compares them in Table 2.3 and asks you to sort their features in Interactive 2.1.
LSD has been used in psychotherapy since 1949, when a clinical study with lower doses showed therapeutically relevant effects (Passie et al., 2022). The British psychiatrist Ronald Sandison began LSD treatment at Powick Hospital near Worcester at the end of 1952 and opened a purpose-built LSD clinic on the hospital grounds in 1955 (Costandi, 2014). At the First European Symposium for Psychotherapy under LSD-25 in 1960, Sandison named the use of repeated, smaller LSD sessions within psychodynamic therapy "psycholytic therapy" (Passie et al., 2022). Over about fifteen years the approach was developed in continental Europe, where it was used at 30 clinical centres and by more than 100 outpatient psychotherapists, and its leading figure was Hanscarl Leuner in Germany (Passie et al., 2022).
The psychedelic model developed in North America. Passie et al. (2022) credit Hoffer and Osmond with developing it in the late 1950s and describe it as combining specific preparation of the patient, high to very high doses, specific surroundings and music, so as to favour transformational insights and mystical experiences in one or two sessions. Psycholytic approaches were used only minimally in North America, where the psychedelic approach became the dominant method (Passie et al., 2022).
Table 2.3. The psycholytic and psychedelic models of therapy as characterized by Passie, Guss and Krähenmann (2022).
| Feature | Psycholytic therapy | Psychedelic therapy |
|---|---|---|
| Doses reported in the historical literature | Lower doses, for example LSD 30 to 150 micrograms | High doses, for example LSD 250 to 800 micrograms |
| Number of drug sessions | Numerous, about 5 to 25 | One or two |
| Intended effects | Dream-like symbolic imagery, regression, transference and spontaneous insight | A "peak experience" of a mystical kind, self-transcendence and awe |
| Theoretical foundation | Psychoanalytic and psychodynamic theory | Religious and philosophical concepts and transpersonal psychology |
| Procedure | Psychodynamic preparation and analytical discussion of the material in individual and group sessions | Strongly suggestive preparation, a specific environment and structuring music |
| Therapeutic goal | Restructuring of the personality through a process of maturation | Self-transformation through a change in self-experience and perspective |
| Main region | Continental Europe and the United Kingdom | North America |
The doses in Table 2.3 describe historical clinical methods, and Lesson 3 explains dose and dose-response in current trials. Interactive 2.1 applies the table.
Psycholytic, psychedelic or both?
For each statement, choose the model it describes. Feedback appears when you choose, and your score is shown at the end.
Interactive 2.1 shows that the two models differ mainly in dose, number of sessions and goal, while both place the drug inside a relationship with a therapist. Lesson 7 describes how present-day models draw on both traditions. The next part asks what happened when the psychedelic model was tested in randomized trials.
5.1 What the Controlled Trials Found
By the early 1960s, the standard of evidence for new treatments was changing. This part explains that change, describes the randomized trials of LSD for alcohol use disorder that a 2012 meta-analysis pooled and shows what they found when combined.
5.1.1 A New Standard of Evidence
In the United States, the Kefauver Harris Drug Amendments of 1962 required proof of efficacy from controlled clinical trials before a drug could be marketed, and Oram (2014) argues that LSD psychotherapy, which used drug effects to catalyze a psychological treatment, clashed with controlled-trial methodology. Dyck (2005) identifies the same shift as one of two reasons the Saskatchewan experiments failed: the scientific parameters of clinical trials came to require randomized controlled trials, "which the Saskatchewan researchers had failed to construct." Mangini (1998) likewise describes many hypothesis-generating studies with a variety of designs but "relatively few controlled trials."
5.1.2 Six Randomized Trials
Krebs and Johansen (2012) identified six randomized controlled trials of LSD for alcohol use disorder, published between 1966 and 1970, with 536 participants, of whom 325 were assigned to a full dose of LSD and 211 to a control condition. All participants had been admitted to alcohol treatment programs, and every trial used a single dose of LSD. Table 2.4 summarizes the trials. The Canadian trial among them was conducted by Smart and colleagues (1966) at Toronto's Alcoholism and Drug Addiction Research Foundation, the organization that had asked for controlled evidence. Krebs and Johansen (2012) excluded three further randomized trials that reported no usable data on alcohol misuse, among them a trial of LSD for alcohol use disorder and neurosis in Saskatoon (Denson & Sydiaha, 1970).
Table 2.4. The six randomized trials of LSD for alcohol use disorder included in the meta-analysis by Krebs and Johansen (2012).
| Trial | Location | LSD dose (number assigned) | Control condition (number assigned) | Support during the drug session | Follow-up |
|---|---|---|---|---|---|
| Smart et al., 1966 | Toronto, Canada | 800 micrograms (10) | Ephedrine 60 mg (10) or no drug (10) | Interview, then occasional observation; no music; strapped to the bed by a waist belt; drug not named | 6 months |
| Hollister et al., 1969 | Palo Alto, California | 600 micrograms (36) | d-Amphetamine 60 mg (36) | Brief supportive reassurance; music and comfortable furniture | 2 and 6 months |
| Ludwig et al., 1969 | Madison, Wisconsin | About 210 micrograms (132) | No drug (44) | Psychotherapy, hypnosis with psychotherapy, or silent observation | 1 to 12 months |
| Bowen et al., 1970 | Topeka, Kansas | 500 micrograms (22) | LSD 25 micrograms (22) | Supportive reassurance; music, flowers and pictures | 12 months |
| Pahnke et al., 1970 | Baltimore, Maryland | 450 micrograms (73) | LSD 50 micrograms (44) | Extensive preparation; guidance toward a "peak or transcendental experience"; living-room setting | 6 and 12 months |
| Tomsovic and Edwards, 1970 | Sheridan, Wyoming | 500 micrograms (52) | Treatment as usual (45) | Supportive reassurance; music, flowers, pictures and a scenic view | 3 to 12 months |
Source: Krebs and Johansen (2012), Tables 1 and 2.
Table 2.4 shows how differently the trials delivered the same drug. Toronto patients were not told what they were receiving, heard no music and were held to the bed by a waist belt, while the Baltimore trial offered extensive preparation and guidance in a room designed to feel like a living room. Krebs and Johansen (2012) note that concealing the drug or leaving patients alone may have weakened the treatment and increased the risk of adverse events, a point that Lesson 5 develops for set and setting.
5.1.3 What the Trials Found When Combined
Krebs and Johansen (2012) pooled the trials in a random-effects meta-analysis, counting participants lost to follow-up as unimproved. At the first follow-up, the odds of improvement in alcohol misuse were about twice as high with LSD as with control (odds ratio 1.96, 95 percent confidence interval 1.36 to 2.84), with negligible heterogeneity between trials (I2 = 0 percent). Among the five trials that reported yes-or-no outcomes, 185 of 315 LSD patients (59 percent) and 73 of 191 control patients (38 percent) were improved, and the pooled benefit difference was 16 percentage points (95 percent confidence interval 8 to 25), which the authors express as a number needed to treat of six (1 divided by 0.16 is 6.25, which the rounding-up convention of Worked Example 2.1 would report as seven). The effect faded with time. At six months the odds ratio was 1.66 (1.11 to 2.47), and at twelve months, in four trials, it was 1.19 (0.74 to 1.90), an interval that includes no effect.
Passie et al. (2022), by contrast, write that none of the controlled efficacy studies showed significant results in favour of psychedelic peak therapy for alcoholism. Both statements can be accurate if most trials were too small to detect an effect on their own, a common reason for pooling, yet they lead to different emphases, and the conflict is a genuine difference in interpretation. The evidence from these historical trials is therefore mixed and limited by small samples and the methods of the period, and research on newer trials, which Lesson 10 examines, is still evolving. Formula 2.1 sets out the quantities behind the pooled figures.
risk difference = risk with LSD − risk with control
odds = number improved ÷ (number in the group − number improved)
odds ratio = odds with LSD ÷ odds with controlEq 2.1
Worked Example 2.1: Summing the five trials
Krebs and Johansen (2012) report that 185 of 315 LSD patients and 73 of 191 control patients were improved at the first follow-up. These are the five trials with yes-or-no outcomes; the Toronto trial (Smart et al., 1966), with 10 LSD and 20 control patients, reported only a continuous outcome and is left out, which is why the totals are smaller than the 325 and 211 in Table 2.4.
- Risk with LSD: 185 ÷ 315 = 0.587 (58.7 percent).
- Risk with control: 73 ÷ 191 = 0.382 (38.2 percent).
- Risk difference: 0.587 − 0.382 = 0.205, or 20.5 percentage points.
- Odds with LSD: 185 ÷ 130 = 1.423. Odds with control: 73 ÷ 118 = 0.619.
- Odds ratio: 1.423 ÷ 0.619 = 2.30.
- Number needed to treat: 1 ÷ 0.205 = 4.9, which rounds up to 5.
These crude figures are larger than the meta-analytic estimates (a benefit difference of 16 percentage points, which the authors express as a number needed to treat of six, and an odds ratio of 1.96). Summing the counts treats all patients as one trial, while a meta-analysis compares LSD with control inside each trial and then combines the comparisons. Because the trials differed in size, allocation and control-group improvement, the within-trial estimate is the one to report.
Use Calculator 2.1 to repeat the worked example and to explore the two hypothetical presets. Lesson 8 develops the number needed to treat and its uses in reading trial results for practice.
Calculator 2.1 shows that the hypothetical small trial gives a risk difference of 20 percentage points and an odds ratio of 2.25, close to the summed figures, yet rests on only 40 patients, so its estimate would be far less certain. A point estimate therefore needs its confidence interval, as in the results that Krebs and Johansen (2012) report. The box below lists further reasons why the historical trials remain hard to interpret.
Why the historical trials remain hard to interpret
Krebs and Johansen (2012) identify several limitations. The trials described their populations and diagnoses only briefly, no protocol could be obtained, and there were too few trials to examine dose or other treatment variables. Two trials concealed from patients that LSD might be used, and in two the patients were left alone during much of the drug's effect. Two used low-dose LSD as an active placebo, which may have reduced the difference between groups, and blinding, keeping participants and assessors unaware of who received the drug, is difficult with drugs that have strong effects, a problem Lesson 5 examines.
Summary
In the 1950s, Osmond and Hoffer made Saskatchewan a centre of LSD research, first as a model of psychosis and then as a single-session treatment for alcohol use disorder, and Osmond proposed the word "psychedelic" in 1956 correspondence with Huxley and introduced it publicly in 1957. Hollywood Hospital offered private LSD treatment from 1957, with case files opened until 1968 and closure by 1975. Europe developed a psycholytic model of repeated lower-dose sessions and North America a psychedelic model of one or two high-dose sessions. The randomized trials published from 1966 to 1970 were small and varied, and when Krebs and Johansen (2012) pooled six of them, they found a benefit at first follow-up that faded by twelve months, a result that Passie et al. (2022) read differently.
Dyck (2005) gives a second, cultural reason for the end of this research: as LSD became associated with the counterculture, governments criminalized it. LSD also had a darker history in Canada, in experiments that patients never agreed to. Section 3 examines that history and the prohibition that followed.
Key Takeaways
- 3.1 In the 1950s, Humphry Osmond at the Weyburn hospital and Abram Hoffer in the provincial health department made Saskatchewan a centre of LSD research. They first studied LSD and mescaline as a "model psychosis" that might help staff understand patients and support a biochemical account of schizophrenia, work that also produced reforms in hospital design and nursing care. Osmond proposed the word "psychedelic" in 1956 correspondence with Aldous Huxley and introduced it publicly in 1957, marking a shift from imitating illness to revealing and changing the mind.
- 3.2 Researchers reasoned that LSD might reproduce the frightening experience of delirium tremens, which sometimes led people to drink less, and that it could be given before a person reached "rock bottom"; Osmond and Hoffer began this single-session treatment in 1953. The first trials reported unusually high rates of abstinence, but Toronto's Alcoholism and Drug Addiction Research Foundation disputed the results and asked for controlled trials, which set the terms on which the treatment would be judged.
- 4.1 Hollywood Hospital, a private facility in New Westminster, began LSD treatment under J. Ross MacLean in 1957. The BC Archives description records 510 surviving case files opened between 1957 and 1968, more than 800 patients and closure by 1975, while a magazine account reports more than 6,000 sessions and a success rate of 50 to 80 percent. The archive counts patients and files and the magazine counts sessions, and the success rate is the clinic's own claim without a comparison group.
- 4.2 The psycholytic model, named by Ronald Sandison in 1960 and used mainly in Europe, gave about 5 to 25 lower-dose sessions within psychodynamic therapy with the goal of restructuring the personality. The psychedelic model, developed by Hoffer and Osmond in North America, gave one or two high-dose sessions with preparation, a specific setting and music to produce a mystical "peak experience." Both place the drug inside a relationship with a therapist, and they differ in dose, number of sessions, theory and goal.
- 5.1 Summing the five trials with yes-or-no outcomes (185 of 315 improved with LSD, 73 of 191 with control) gives risks of 58.7 and 38.2 percent, a risk difference of 20.5 percentage points, an odds ratio of 2.30 and a number needed to treat of about 5. These crude figures exceed the meta-analytic estimates of Krebs and Johansen (2012), a benefit difference of 16 percentage points and an odds ratio of 1.96, because a meta-analysis compares LSD with control within each trial before combining the comparisons. The benefit faded to an odds ratio of 1.19 (0.74 to 1.90) at twelve months, and small, varied trials with concealment and weak blinding remain hard to interpret.
Reflection
Two randomized trials of LSD for alcohol use disorder in the 1960s gave the drug in very different conditions. In Toronto (Smart et al., 1966), 10 patients received 800 micrograms of LSD; they were not told the drug's name, heard no music, were strapped to the bed by a waist belt and were observed only occasionally. In Baltimore (Pahnke et al., 1970), 73 patients received 450 micrograms after extensive preparation, with guidance aimed at a "peak or transcendental experience" in a living-room setting. A 2012 meta-analysis by Krebs and Johansen pooled these and four other trials (536 participants) and reported an odds ratio for improvement of 1.96 (95 percent confidence interval 1.36 to 2.84) at first follow-up and 1.19 (0.74 to 1.90) at twelve months, with negligible heterogeneity between trials. In 120 to 250 words, explain how differences in setting and support could affect what this pooled estimate means, and name three details you would want a modern trial to report so that its results could be interpreted.
Minimum 20 characters required.
Question 1: What rationale did early researchers give for treating alcohol use disorder with LSD?
Question 2: Which statement best reflects the archival record of LSD treatment at Hollywood Hospital?
Question 3: Which feature belongs to the psycholytic model of therapy?
Question 4: Krebs and Johansen (2012) report an odds ratio for improvement of 1.96 (1.36 to 2.84) at first follow-up and 1.19 (0.74 to 1.90) at twelve months. What is the best interpretation?
Coercion and Prohibition: MKUltra, the Allan Memorial Institute and the 1971 Convention
Content note
This section describes non-consensual experimentation on psychiatric patients, including prolonged drug-induced sleep, intensive electroshock and lasting memory loss, and the covert drugging of people who did not know they were being tested. If you would like support, the 9-8-8 Suicide Crisis Helpline can be reached by call or text at 9-8-8, and the Hope for Wellness Help Line for Indigenous people is available at 1-855-242-3310.
Introduction
Section 2 described therapeutic research whose methods were contested. This section turns to experiments that were coercive, and then to the legal changes that ended the first research era. Dyck (2005) observes that "in the popular mind," LSD research in psychiatry "has long been associated with the CIA-funded experiments conducted by Ewen Cameron" at the Allan Memorial Institute in Montreal, although, as Dyck shows, a host of medical researchers of the period explored LSD for its potential therapeutic value. Separating the two histories helps explain why consent and oversight are central to psychedelic practice today, as Lessons 7 and 12 show.
Learning Objectives
- 6.1 Describe the Central Intelligence Agency's MKUltra program using the figures reported to the United States Senate in 1977.
- 6.2 Describe Ewen Cameron's psychic driving and depatterning at the Allan Memorial Institute in Montreal and how they were funded.
- 6.3 Apply the principles of the Nuremberg Code (1947) to documented practices of the period, including Cameron's work and the concealment of LSD in some therapeutic trials.
- 6.4 Summarize Canada's responses to former patients, from the Cooper report of 1986 and the payments of 1992 to the class action authorized in 2025.
- 7.1 Explain how the drug regulations of 1962, the 1971 Convention on Psychotropic Substances and Canada's drug schedules ended the first research era, and how Canada and the United States reserved ceremonial peyote use.
6.1 MKUltra
MKUltra was a program of the United States Central Intelligence Agency (CIA). This part describes what the agency's surviving records revealed about it in 1977.
Director of Central Intelligence Allen Dulles approved MKUltra on 13 April 1953 as a special funding mechanism for sensitive research. A 1963 survey by the CIA's Inspector General, quoted at a Senate hearing in 1977, gave as one reason for its secrecy that "research in the manipulation of human behavior is considered by many authorities in medicine and related fields to be professionally unethical" (United States Senate, 1977). The records of the program's activities were destroyed in January 1973 at the instruction of the then Director, Richard Helms. In 1977, however, an employee responding to freedom-of-information requests found financial folders that had been sent to a records centre in 1970 and had escaped destruction, and the CIA Director, Admiral Stansfield Turner, described them to a joint hearing of two Senate committees on 3 August 1977 (United States Senate, 1977). Table 2.5 summarizes what the hearing reported.
Table 2.5. What the surviving MKUltra financial records showed, as reported to the United States Senate on 3 August 1977.
| Item | Reported figure |
|---|---|
| Subprojects related to behavioural modification, drug acquisition and testing, or covert drug administration | 149 |
| Subprojects researching behavioural drugs or alcohol that definitely involved tests on human volunteers | 14 |
| Subprojects in the same category involving tests on unwitting subjects | 6 |
| Non-government researchers and assistants named | 185 |
| Institutions where work was done or with which researchers were affiliated | 80, including 44 colleges or universities, 15 research foundations or chemical or pharmaceutical companies, 12 hospitals or clinics and 3 penal institutions (74 of the 80; the testimony does not give the type of the other 6) |
| Funding method | "Cut-out" (intermediary) funding mechanisms used to conceal CIA sponsorship |
Source: United States Senate (1977), testimony of the Director of Central Intelligence.
At the same hearing, Senator Edward Kennedy recalled earlier testimony that the agency's covert drug tests had included LSD given to "unwitting subjects in social situations," that the test subjects "were seldom accessible beyond the first hours of the test," and that in some cases a subject "became ill for hours or days, and effective followup was impossible" (United States Senate, 1977). Secrecy, hidden funding and testing without consent form the background to the Montreal experiments.
6.2 Ewen Cameron and the Allan Memorial Institute
The Canadian chapter of this history took place at a McGill University psychiatric institute in Montreal. This part describes the treatments its director developed, how they were funded and what patients experienced, drawing on an analysis of Cameron's publications by Torbay (2023), the Canadian Encyclopedia and a Federal Court decision.
6.2.1 Psychic Driving and Depatterning
At the invitation of the neurosurgeon Wilder Penfield, the Scottish-born psychiatrist D. Ewen Cameron became the first director of the Allan Memorial Institute, which he established in 1943 in Ravenscrag, a Montreal mansion that had belonged to Sir Hugh Allan (Noakes, 2021; Torbay, 2023). In published papers, Cameron described "psychic driving," in which patients heard recorded statements about themselves played back many times, and a "depatterning" treatment for schizophrenia (Cameron, 1956; Cameron et al., 1962). In one early study of psychic driving, in 1954 and 1955, a patient became "restless and anxious" during ten minutes of replayed statements and begged the experimenter to stop (Torbay, 2023). Torbay (2023) also summarizes a contract that Cameron signed in 1957 for research combining four elements: the breaking down of patients' patterns of behaviour by particularly intense electroshock, which he called depatterning; the repetition of a prearranged verbal signal for 16 hours a day for six to seven days; partial sensory isolation during the repetition; and continuous drug-induced sleep for seven to ten days afterward. The Canadian Encyclopedia adds that some patients were given large doses of LSD and that one patient's drug-induced sleep reportedly lasted 86 days (Noakes, 2021).
For the purposes of Canada's later compensation scheme, a depatterned person was one who received full or substantial depatterning treatment from Cameron at the institute between 1950 and 1965, defined as prolonged sleep followed by massive electroshock treatments that reduced the patient's mind to a childlike state, with all three elements required (Pleszkewycz v. Canada, 2012). An application for a class action filed in 2019 describes one patient, Charles Tanny, as receiving more than 50 days of insulin-induced "sleep therapy" with several sedative drugs and frequent intensive electroshock of the Page-Russell type, in which shocks continued during convulsions, after which he experienced near total memory loss and disorientation that never fully resolved (Torbay, 2023). These are allegations made in litigation, and Canada's courts had not ruled on them as of October 2026.
6.2.2 Who Paid, and Who Knew
Funding came from two governments. In January 1957, the CIA began subsidizing Cameron's experiments as Subproject 68 of MKUltra, giving him about 69,000 dollars over the following years through a front organization, the Society for the Investigation of Human Ecology; Torbay (2023) concludes that Cameron was probably never aware that the money came from the CIA. Canada's Department of National Health and Welfare also funded the research through federal grants, about half a million dollars between 1950 and about 1965 according to the Canadian Encyclopedia (Noakes, 2021; Thompson, 2017). Patients and their families did not know at the time that the CIA was a funder (Thompson, 2017). Cameron had been among the psychiatrists sent to the Nuremberg trials to evaluate the mental capacity of the accused, so he would have been aware of the ethical standard that those trials produced (Torbay, 2023), which the box below sets out.
The Nuremberg Code, 1947
The Nuremberg Code was issued with the judgment of the American military tribunal in the trial of Nazi doctors in 1947 and published in the official record of the trials in 1949 (United States Government, 1949). It sets out ten principles for permissible medical experiments. Its first principle states that "the voluntary consent of the human subject is absolutely essential," which requires legal capacity, freedom from force, fraud, deceit or coercion, and knowledge of the nature, duration and purpose of the experiment and its hazards. Other principles require that an experiment yield fruitful results for society and rest on prior animal experimentation and knowledge (principles 2 and 3); that it "avoid all unnecessary physical and mental suffering and injury" (principle 4); that proper preparations and facilities protect the subject against even remote possibilities of injury (principle 7); that the subject be "at liberty to bring the experiment to an end" (principle 9); and that the scientist be prepared to stop it if continuing is likely to cause injury, disability or death (principle 10).
6.3 Applying the Nuremberg Code
The Code existed a decade before the CIA began funding the Montreal experiments in 1957, yet the government's investigator later reached a mixed conclusion about them. This part presents that conclusion, and Interactive 2.2 applies the Code.
In February 1986, George Cooper, a lawyer retained by the federal Minister of Justice, reported on the research and treatment at the institute and on the government's potential liability. Cooper concluded that depatterning was not based on sound scientific or medical principles, yet he found it acceptable by the standards of its time and concluded that the government could not be expected to bear responsibility (Pleszkewycz v. Canada, 2012). His finding illustrates a recurring argument in the history of research ethics, that conduct should be judged by the standards of its own time. The Nuremberg Code shows that a written standard of voluntary consent already existed in 1957, so that argument has limits even on its own terms. Interactive 2.2 asks you to match each documented practice to the principle it most clearly conflicts with.
A consent audit: which principle of the Nuremberg Code?
Each statement describes a documented practice from this lesson. Choose the principle of the Nuremberg Code that it conflicts with most clearly. Some principles apply to more than one statement.
Interactive 2.2 shows that the most frequent failure was the absence of informed consent, and that this failure was not confined to intelligence-funded work: two of the six randomized LSD trials described in Section 2 also concealed the drug from patients (Krebs & Johansen, 2012). Health Canada's expectations for clinical trials of psychedelic-assisted psychotherapy, published on 5 December 2022, state that written informed consent must be obtained before a person takes part and that consent for touch should be obtained before the drug is given and again at the time of any touch (Health Canada, 2022), and Lesson 7 examines consent in preparation for a dosing session. The next part follows what Canada did for the former patients once the Montreal experiments became public.
George Cooper concluded in 1986 that depatterning was not based on sound scientific or medical principles yet was acceptable by the standards of its time. Write a short paragraph that evaluates this conclusion using three facts from this section: the date of the Nuremberg Code, Cameron's own presence at the Nuremberg trials, and the 1963 Inspector General's statement that many authorities considered research on the manipulation of behaviour professionally unethical. Then state one reason someone might offer in support of Cooper's view, and say what evidence would be needed to test it.
6.4 Canada's Responses to Former Patients
The Montreal experiments became widely known in Canada only decades after they ended, and the responses have unfolded over more than forty years. The tabs below divide that history into three periods, and Figure 2.2 places the main events on a single time line.
The surviving MKUltra records were described to the United States Senate in 1977 (United States Senate, 1977). Canadians first learned of the Montreal experiments through a 1980 episode of the CBC program The Fifth Estate (Noakes, 2021). Former patients sued the United States government, and in 1988 nine survivors received compensation from it (Noakes, 2021).
The Cooper report of February 1986 discussed ex gratia payments, made without admission of legal liability, without recommending them. The government nonetheless adopted an order respecting ex gratia payments to persons depatterned at the Allan Memorial Institute between 1950 and 1965 (P.C. 1992-2302), which authorized payments of 100,000 dollars to eligible persons, with claims reviewed by a medical examiner and decided by a committee of the Department of Justice (Pleszkewycz v. Canada, 2012). The Minister of Justice, Kim Campbell, described them as made for "compassionate and humanitarian reasons" (Thompson, 2017). The Canadian Encyclopedia reports that 77 survivors received compensation and that more than 250 claimants were denied (Noakes, 2021); CBC News put the number paid at an estimated 70 (Thompson, 2017). Rejected applicants were told that they had not been depatterned enough to qualify (Thompson, 2017).
After the payment program closed, the federal government quietly settled claims from a handful of former patients, according to the lawyer Alan Stein, who had won compensation for Gail Kastner in 2004 and an out-of-court settlement for Janine Huard in 2007 (Thompson, 2017). In 2017 the government paid 100,000 dollars to Alison Steel, the daughter of the former patient Jean Steel, to settle an action filed in September 2015 (Thompson, 2017). A later action by Alison Steel and other relatives of former patients, also represented by Stein, was dismissed by the Superior Court of Québec on 29 October 2025, according to class counsel (Consumer Law Group, 2026). In 2012, the Federal Court dismissed a judicial review of a 1994 refusal of compensation (Pleszkewycz v. Canada, 2012). In 2019, Julie Tanny applied to the Superior Court of Québec for authorization of a class action on behalf of former patients and their families (Torbay, 2023). The United States government was dismissed from the case on grounds of state immunity, and on 31 July 2025 the court authorized the class action against the Government of Canada, the Royal Victoria Hospital and McGill University; according to class counsel, the Court of Appeal of Québec refused the hospital permission to appeal the authorization in November 2025 (Consumer Law Group, 2026). As of January 2026 the action had been authorized but not decided, and a trial was still required to determine fault and compensation (Éducaloi, 2026); class counsel's case page listed no judgment on the merits or settlement as of October 2026 (Consumer Law Group, 2026).
Figure 2.2 shows that the most substantial payments came more than twenty-five years after the experiments ended, and that the eligibility rule, which required proof of full or substantial depatterning, left most claimants without compensation. The questions of responsibility that the class action raises remain open as of October 2026.
7.1 Prohibition and the End of the First Research Era
While the Montreal experiments remained secret, LSD's legal status was changing in public. This part describes three layers of control, national drug regulation in the early 1960s, the criminalization that followed the spread of non-medical use, and the international treaty of 1971, and then explains what continued after the research stopped.
7.1.1 Regulation in the Early 1960s
The first restrictions came through drug safety law. In the United States, the Kefauver Harris Drug Amendments of 1962, described in Section 2, required controlled evidence of efficacy (Oram, 2014). In Canada, Dyck (2015) writes that the issue "first arose in 1962 amid the thalidomide scandal," when regulators considered placing LSD under restrictions similar to those placed on thalidomide. Canada allowed LSD research to continue, but researchers had to apply directly to the federal health minister, and psychedelic research faded in the early 1960s; Osmond himself left Saskatchewan in 1961 for Princeton University (Dyck, 2019).
7.1.2 Criminalization
By the end of the decade, concern about non-medical use had grown (Dyck, 2019). Dyck (2005) describes how, "as LSD became increasingly associated with student riots, antiwar demonstrations, and the counterculture, governments intervened to criminalize the drug, restricting and then terminating formal medical research into its potential therapeutic effects." Dyck (2006) adds that media attention to these associations weakened LSD's standing as a clinical treatment. In Canada, Parliament made possession of LSD and other "restricted drugs" a criminal offence in August 1969 (Commission of Inquiry into the Non-Medical Use of Drugs, 1973), and HSCI 180 Lesson 2 describes that law and the Le Dain Commission's inquiry into non-medical drug use (1969 to 1973).
7.1.3 The 1971 Convention on Psychotropic Substances
International control followed. The Convention on Psychotropic Substances was adopted in Vienna on 21 February 1971 and entered into force on 16 August 1976, and as of 17 October 2026 it has 184 parties (United Nations Treaty Collection, 2026). HSCI 180 Lesson 11 explains how its schedules work. For substances in Schedule I, which as amended and as of October 2026 includes LSD, psilocybin, psilocin, mescaline, DMT and MDMA, Article 7 requires parties to "prohibit all use except for scientific and very limited medical purposes by duly authorized persons, in medical or scientific establishments which are directly under the control of their Governments or specifically approved by them," and to require licences and detailed records (United Nations, 1971).
The Convention also made room for ceremonial use of plants. Article 32, paragraph 4, allows a state "on whose territory there are plants growing wild which contain psychotropic substances from among those in Schedule I and which are traditionally used by certain small, clearly determined groups in magical or religious rites" to make reservations concerning those plants (United Nations, 1971). The United States excepted peyote harvested and distributed for use by the Native American Church in its religious rites. Canada acceded on 10 September 1988 with a reservation for peyote, noting that its population includes groups who use such substances "in magical or religious rites" and that the substance occurs "in plants which grow in North America but not in Canada"; because the plant does not grow wild in Canada, Canada made its reservation under paragraph 3 of the article, and it was deemed permitted when no party objected (United Nations Treaty Collection, 2026). Table 2.6 shows how these international entries correspond to Canada's current law.
Table 2.6. Selected psychedelics in Schedule I of the 1971 Convention and in Canada's Controlled Drugs and Substances Act, as of October 2026.
| Substance | 1971 Convention, as amended | Controlled Drugs and Substances Act (Canada) |
|---|---|---|
| LSD | Schedule I | Schedule III |
| Psilocybin and psilocin | Schedule I | Schedule III |
| Mescaline | Schedule I | Schedule III, "but not peyote (lophophora)" |
| DMT | Schedule I | Schedule III |
| Harmaline (a beta-carboline alkaloid) | Not listed in Schedule I | Schedule III |
| Peyote, the plant | Reservations permitted for traditional ceremonial use; reserved by Canada and the United States | Excluded from the mescaline entry |
Sources: United Nations (1971), list of substances in Schedule I; Controlled Drugs and Substances Act, Schedule III (Justice Laws Website, accessed October 2026); United Nations Treaty Collection (2026).
The Controlled Drugs and Substances Act, which came into force in 1997 (Canada Gazette, 2022), carried these substances forward. As Table 2.6 shows, Canada's law follows the treaty closely for the synthetic and isolated compounds while leaving room for the plant that a Canadian church uses in ceremony. Lesson 11 explains the routes by which these Schedule III substances can be lawfully used in treatment today.
7.1.4 What Ended and What Continued
Mangini (1998) summarizes the outcome: after twenty-five years of study, "a combination of flawed methodology, uneven results and social reprehension led to the abandonment of research on the therapeutic use of psychedelic drugs." Dyck (2019) writes that psychedelic research then remained relatively quiet for about fifty years. Some practice continued, however. Hollywood Hospital operated until 1975 (Royal BC Museum, 2013), ceremonial peyote use continued and gained statutory protection in the United States in 1994, and Canada's 1988 reservation preserved room for ceremonial peyote use. The first research era therefore ended in the clinic and the laboratory while ceremonial traditions persisted outside them.
Summary
MKUltra, approved in 1953, funded 149 subprojects on behavioural modification and drugs, including tests on people who did not know they were being drugged, through intermediaries that concealed CIA sponsorship. At the Allan Memorial Institute, Ewen Cameron combined intensive electroshock, prolonged drug-induced sleep, repeated recorded messages and, for some patients, LSD, with funding from the CIA and from Canada's Department of National Health and Welfare. Canada paid 100,000 dollars each to 77 former patients from 1992 (an estimated 70 according to CBC News), later settled a few individual claims, including one reported in 2017, and a class action against Canada, the Royal Victoria Hospital and McGill University was authorized in 2025. Over the same decades, drug safety law in 1962, criminalization later in the decade and the 1971 Convention ended the first research era, while reservations for peyote preserved ceremonial use.
Research with psychedelics did not stop entirely, and in the 1980s a small number of clinicians and organizations began to argue for its return. Section 4 follows that revival from the emergency scheduling of MDMA in 1985 to Canada's first legal exemptions for psilocybin in 2020.
Key Takeaways
- 6.1 MKUltra, approved by the Director of Central Intelligence in 1953, funded research on behaviour modification and drugs through "cut-out" mechanisms that concealed CIA sponsorship. Financial records that escaped the destruction of 1973, reported to the United States Senate in 1977, showed 149 related subprojects, 6 involving tests on unwitting subjects, 185 named researchers and 80 institutions, and earlier testimony described LSD given to unwitting people in social situations without effective follow-up.
- 6.2 At the Allan Memorial Institute in Montreal, Ewen Cameron combined psychic driving, the repeated playback of recorded statements, with depatterning: intensive electroshock, prolonged drug-induced sleep, partial sensory isolation and, for some patients, large doses of LSD, which left some with lasting memory loss. The CIA funded the work from 1957 as Subproject 68 through the Society for the Investigation of Human Ecology, Canada's Department of National Health and Welfare also funded it, and patients and their families did not know of the CIA's role.
- 6.3 The Nuremberg Code of 1947 made voluntary, informed consent absolutely essential and required a sound scientific basis, avoidance of unnecessary suffering, protection of subjects and their liberty to end an experiment. The CIA's covert tests and Cameron's work breached these principles, and two of the randomized LSD trials also concealed the drug from patients. Cooper's 1986 conclusion that depatterning was acceptable by the standards of its time is weakened by the existence of the Code, Cameron's own presence at the Nuremberg trials and the CIA's 1963 acknowledgement that such research was widely considered unethical.
- 6.4 Canadians learned of the Montreal experiments in 1980, and the United States compensated nine survivors in 1988. Canada authorized ex gratia payments of 100,000 dollars in 1992, paid to 77 survivors (an estimated 70 according to CBC News) while more than 250 claimants were denied under a strict depatterning test, and later settled some individual claims, including one in 2017. A class action against Canada, the Royal Victoria Hospital and McGill University was authorized in 2025 and, as of January 2026, awaits trial.
- 7.1 Drug safety law after 1962 raised the bar for evidence, and in Canada researchers had to apply directly to the federal health minister; as LSD became linked to the counterculture, governments criminalized it, and Canada made possession an offence in 1969. The 1971 Convention on Psychotropic Substances limits Schedule I substances to scientific and very limited medical use, while Article 32 allowed reservations for ceremonial plant use: the United States excepted peyote for the Native American Church, and Canada acceded in 1988 with a reservation for peyote. As of October 2026, Canada's Controlled Drugs and Substances Act lists mescaline "but not peyote," so ceremonial use persisted while clinical research stopped.
Reflection
In February 1986, George Cooper, a lawyer retained by the federal Minister of Justice, concluded that Ewen Cameron's depatterning treatment at the Allan Memorial Institute in Montreal was not based on sound scientific or medical principles, yet was acceptable by the standards of its time, and that the government could not be expected to bear responsibility. The Nuremberg Code, issued in 1947, states that the voluntary consent of the human subject is absolutely essential; Cameron had been among the psychiatrists sent to the Nuremberg trials; and patients and their families did not know that the CIA helped fund the research from 1957. In 1992 Canada authorized ex gratia payments of 100,000 dollars to people who could show that they had received full or substantial depatterning (prolonged sleep followed by massive electroshock reducing the mind to a childlike state); 77 people were paid and more than 250 claimants were denied. In 120 to 250 words, evaluate Cooper's "standards of the time" argument and comment on the fairness of the 1992 eligibility rule.
Minimum 20 characters required.
Question 1: According to the 1977 United States Senate hearing, how many MKUltra subprojects involved tests on unwitting subjects?
Question 2: How did the CIA fund Ewen Cameron's experiments at the Allan Memorial Institute?
Question 3: Which conclusion did George Cooper's 1986 report reach about depatterning?
Question 4: What does Article 32, paragraph 4, of the 1971 Convention on Psychotropic Substances allow?
The Revival: From MDMA's Scheduling to Canada's First Psilocybin Exemptions
Introduction
Section 3 showed how drug safety law, criminalization and the 1971 Convention ended the first research era. This section follows the return of research and legal access, from the scheduling of MDMA and the founding of new research organizations, through two experiments on mystical experience and a retracted study of harm, to the reopening of legal access in Canada between 2017 and 2022. It closes with a time line of the whole lesson and the lessons for practice that the course draws from it.
Learning Objectives
- 8.1 Trace MDMA's path from psychotherapy in the late 1970s to emergency scheduling in 1985 and permanent Schedule I placement in the United States in 1988.
- 8.2 Describe the founding of the Multidisciplinary Association for Psychedelic Studies (1986) and the Heffter Research Institute (1993) and their roles in the revival.
- 8.3 Compare the design of the Good Friday Experiment (1962) with Griffiths et al. (2006), and explain what Doblin's 1991 follow-up revealed.
- 8.4 Explain why a 2002 study of MDMA neurotoxicity was retracted and what the episode teaches about evaluating claims of harm.
- 9.1 Describe how legal access reopened in Canada through the 2017 ayahuasca church exemptions, the 2020 psilocybin exemptions supported by TheraPsil and the January 2022 Special Access Program amendments.
- 10.1 Place Canadian and international events from ancient times to 2022 in sequence.
- 10.2 Identify the lessons for practice that the course draws from this history.
8.1 MDMA: From Therapy Rooms to Schedule I
MDMA's scheduling in the United States became a test of whether medical use could be weighed before a substance was banned. Lesson 9 connects this history to the later trials of MDMA-assisted therapy.
The chemist Alexander Shulgin played an important part in MDMA's modern history, although others had synthesized it before him. By his own account he synthesized it in 1965 without trying it; in the mid-1970s he learned of its unusual effects, re-synthesized it and tried it himself in September 1976; and in 1977 he gave it to the psychotherapist Leo Zeff, who used it as an adjunct to psychotherapy and introduced it to other therapists (Benzenhöfer & Passie, 2010). In 1978, Shulgin and David Nichols published a paper on MDMA's pharmacological action in humans (Benzenhöfer & Passie, 2010).
The United States Drug Enforcement Administration (DEA) proposed placing MDMA in Schedule I in July 1984, and psychiatrists and researchers, including Lester Grinspoon and George Greer, obtained a hearing before an administrative law judge (MAPS, n.d.-b). Table 2.7 shows the sequence of decisions that followed.
Table 2.7. The scheduling of MDMA in the United States, 1984 to 1988.
| Date | Action |
|---|---|
| 27 July 1984 | The DEA publishes a proposal to place MDMA in Schedule I, and a scheduling hearing is requested. |
| 31 May 1985 | The DEA publishes a temporary (emergency) placement of MDMA in Schedule I, effective 1 July 1985. |
| 22 May 1986 | Administrative Law Judge Francis L. Young recommends that MDMA be placed in Schedule III, which would have allowed medical use. |
| 13 November 1986 | The DEA's final order placing MDMA in Schedule I takes effect. |
| 27 January 1988 | After an appeals court asks the DEA to reconsider its interpretation of "accepted medical use," MDMA is removed from Schedule I. |
| 23 March 1988 | MDMA is placed in Schedule I again, where it remained as of October 2026. |
Sources: DEA Diversion Control Division (2026), scheduling actions in chronological order (50 FR 23118; 51 FR 36552; 53 FR 2225; 53 FR 5156); MAPS (n.d.-b), documents from the DEA scheduling hearing, 1984 to 1988.
Table 2.7 shows that the administrative law judge who heard the evidence recommended a schedule permitting medical use, and that the agency overruled him. MDMA was later added to Schedule I of the 1971 Convention (Section 3), and the regulatory history of MDMA-assisted therapy since 2017 is the subject of Lesson 9.
8.2 New Organizations for a New Era
Two organizations founded after MDMA's scheduling became central to the revival, and this part describes each from its own published account.
Rick Doblin founded the Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986, in the aftermath of MDMA's scheduling, so that research on the healing potential of MDMA and other psychedelics could continue (MAPS, n.d.-a). MAPS later created a public benefit company to develop MDMA-assisted therapy, which was renamed Lykos Therapeutics in early 2024 (MAPS, n.d.-a) and later Resilient Pharmaceuticals (HCPLive, 2026); Lesson 9 follows that program's regulatory history. The Heffter Research Institute was incorporated in New Mexico in 1993 as a non-profit organization, with David Nichols as co-founder and president and a founding board that included Mark Geyer, George Greer, Charles Grob and Dennis McKenna (Nichols, 2018). Nichols (2018) writes that Heffter supported the studies of psilocybin-assisted therapy for depression and anxiety in people with cancer published from Johns Hopkins and New York University in 2016, as well as pilot studies in alcohol and nicotine addiction, which Lessons 8 and 10 examine.
8.3 Mystical Experience in Two Experiments
A 2006 study revisited a question that the Good Friday Experiment had tested in 1962. This part describes the earlier experiment, the follow-up that exposed its flaws and the 2006 study, and Table 2.8 compares them.
8.3.1 The Good Friday Experiment and Its Follow-Up
On Good Friday, 20 April 1962, Walter Pahnke gave 20 Protestant divinity students, arranged in ten matched pairs and assigned within each pair by a coin toss, either 30 mg of psilocybin or nicotinic acid, an active placebo, before a service at Boston University's Marsh Chapel (Doblin, 1991). Pahnke's original follow-up took place at six months. Between November 1986 and October 1989, 24 to 27 years later, Rick Doblin located 19 of the 20 subjects and interviewed 16 of them, 7 from the psilocybin group and 9 from the control group (Doblin, 1991).
Doblin found that the original report had understated the difficulties. He wrote that difficult psychological experiences were "significantly under-emphasised in Pahnke's thesis," and that one subject "was actually given a shot of thorazine," a tranquilizing drug, during the service, an omission for which he found "no justification" (Doblin, 1991). He also concluded that "the double-blind was broken during the service as the psychoactive effects of the psilocybin deepened," which "makes it impossible to determine the relative contributions of psilocybin and suggestion" (Doblin, 1991). The follow-up thus shows two problems that recur in later research, incomplete reporting of adverse events and the difficulty of keeping participants unaware of whether they received a drug with strong effects.
8.3.2 Griffiths et al. (2006)
Griffiths, Richards, McCann and Jesse (2006), at Johns Hopkins University, gave psilocybin to 36 adults with no previous use of psychedelics (described in the study as hallucinogen-naïve) who took part regularly in religious or spiritual activities. Thirty volunteers received psilocybin (30 mg per 70 kg of body weight) and methylphenidate (40 mg per 70 kg), an active comparison drug, in counterbalanced order in sessions two months apart, and to obscure the design six more volunteers received methylphenidate in their first two sessions and unblinded psilocybin in a third. The eight-hour sessions were conducted individually, volunteers were encouraged to close their eyes and direct their attention inward, and community observers later rated changes in volunteers' attitudes and behaviour (Griffiths et al., 2006).
The university's announcement of the results reported that about one-third of the volunteers rated the psilocybin experience as the single most spiritually significant of their lives and more than two-thirds rated it among their five most meaningful and spiritually significant experiences, and that two months later 79 percent reported moderately or greatly increased well-being or life satisfaction (Johns Hopkins Medical Institutions, 2006). The same announcement reported that "about a third of subjects reported significant fear, with some also reporting transient feelings of paranoia." The study was funded by the National Institute on Drug Abuse and the Council on Spiritual Practices (Johns Hopkins Medical Institutions, 2006). In a 2022 systematic review, mystical experience was associated with symptom reduction in ten of twelve therapy studies, but most of the studies were small and half were open-label, so the link is supported mainly by early studies and research on it is still evolving (Ko et al., 2022). Lesson 5 examines how mystical-type experiences are measured and whether they predict later benefit.
Table 2.8. The Good Friday Experiment (1962) and Griffiths et al. (2006) compared.
| Feature | Good Friday Experiment, 1962 | Griffiths et al., 2006 |
|---|---|---|
| Participants | 20 Protestant divinity students | 36 adults with no previous psychedelic use and regular religious or spiritual practice |
| Design | Matched pairs assigned by coin toss; one session in a group setting | Within-person comparison of psilocybin and methylphenidate in counterbalanced order, with six extra volunteers to obscure the design |
| Comparator | Nicotinic acid, an active placebo | Methylphenidate, an active comparison drug |
| Setting | A Good Friday service in a chapel | Individual eight-hour sessions, with encouragement to close the eyes and direct attention inward |
| Follow-up | Six months; independent follow-up after 24 to 27 years | Two months, including ratings by community observers |
| Reporting of difficulties | Difficult experiences under-emphasized and a tranquilizer injection omitted | Significant fear in about a third of volunteers reported |
Sources: Doblin (1991); Griffiths et al. (2006); Johns Hopkins Medical Institutions (2006).
Table 2.8 shows that the 2006 study addressed several weaknesses of the 1962 experiment, including the choice of comparator, the individual setting and the reporting of fear, while keeping its central question. Neither study could fully prevent participants from recognizing psilocybin's effects, a problem that Lesson 5 discusses under the heading of functional unblinding.
8.4 Contested Evidence: The Ricaurte Retraction
The revival depended on evidence about harms as well as benefits, and one widely reported study of harm turned out to be wrong. The box after the account of the study explains what a retraction is.
In September 2002, the journal Science published a study by George Ricaurte and colleagues reporting that nonhuman primates given several sequential doses of MDMA, in a regimen modelled on human recreational use, developed "severe brain dopaminergic neurotoxicity" in addition to less pronounced damage to serotonin neurons. The authors suggested that people who use MDMA recreationally "may unwittingly be putting themselves at risk" of neuropsychiatric disorders related to dopamine or serotonin deficiency (Ricaurte et al., 2002). In September 2003, the authors retracted the report after discovering that "the drug used to treat all but one animal in that report came from a bottle that contained d-methamphetamine instead of the intended drug, racemic MDMA," which they attributed to a labelling error (Ricaurte et al., 2003).
What a retraction means
A retraction is a formal notice, published by a journal, that a paper's findings should no longer be relied on. Retractions can follow honest error, as in the mislabelled bottle of 2002, or misconduct, and the notice usually states which. The retracted paper remains visible with a label, so readers can see what was claimed and why it was withdrawn. When you cite a study, check whether it has been retracted or corrected; Lesson 9 describes the retraction of three papers on MDMA-assisted therapy in 2024.
The Ricaurte episode carries three lessons for reading the evidence. A single animal study, however prominent, establishes little about human risk until it is replicated, a point that Lesson 4 develops for animal and cell findings. The identity and quality of a study drug must be verified, because the result depended entirely on what was in the bottle. Claims about harm deserve the same scrutiny as claims about benefit. Lesson 6 reviews what current evidence shows about MDMA's risks.
9.1 Canada Reopens Legal Access
In Canada, legal access to psychedelics reopened through exemptions before any psilocybin or MDMA product had been approved. This part describes the exemptions of 2017 and 2020 and the regulatory change of January 2022, which Lesson 11 places among the full set of access routes.
9.1.1 Ayahuasca Churches, 2017
Subsection 56(1) of the Controlled Drugs and Substances Act allows the federal Minister of Health to exempt a person or class of persons from the Act if the Minister considers the exemption necessary for a medical or scientific purpose or otherwise in the public interest (Carolino, 2020). Exemptions for ayahuasca churches have used this power. According to the founder of the Santo Daime church Céu do Montréal, the church applied to Health Canada after a shipment was seized in 2000; an exemption granted in 2006 was to be issued only once Brazil permitted export, which was delayed for years, the request was denied in 2012, and a new joint application with the União do Vegetal was granted in June 2017 (Rochester, 2017). The exemption allowed the church to import and serve its sacrament in its rituals for two years, renewable, subject to conditions that included screening of members and visitors for health and medication contraindications, use only by designated registered members and supply from a registered Brazilian church (Rochester, 2017). The non-profit International Center for Ethnobotanical Education, Research and Service dates the exemptions to 5 June 2017 and reports that three more Santo Daime groups, in Montreal, Val-David and Toronto, received exemptions in May 2019 (ICEERS, 2019).
9.1.2 The First Psilocybin Exemptions, 2020
Case 2.2 summarizes how the first exemptions for psilocybin were obtained, using legal and news reports from 2020 to 2025.
TheraPsil, a non-profit organization based in Victoria, British Columbia, was founded in 2019 by the psychotherapist Bruce Tobin and Spencer Hawkswell to seek legal access to psilocybin-assisted therapy, initially for palliative patients (TheraPsil, 2026; James, 2020). An application begun in 2017 was refused in March 2020, and on review the federal Minister of Health, Patty Hajdu, approved individual applications on compassionate grounds (Carolino, 2020). On 4 August 2020, it was announced that subsection 56(1) exemptions had been granted to four Canadians with incurable cancer, allowing them to possess and use psilocybin to treat end-of-life distress, with applications supported by TheraPsil (Bokshowan & Haight, 2020). TheraPsil described this as the first legal use of psilocybin by a patient since the drug became illegal in Canada in 1974, a claim that reports attribute to the organization (Carolino, 2020). In December 2020, Health Canada granted exemptions to 16 health care professionals to possess and consume psilocybin as part of a training program, for one year and with detailed record keeping (Petrovich, 2020); the Federal Court of Appeal later recorded that 19 substantively identical practitioner exemptions were granted in 2020 as a whole, so the first report of 16 did not include all of them (Toth v. Canada, 2025). No official total of patient exemptions has been published; CBC News reported in February 2022 that Health Canada had granted exemptions to 79 patients since August 2020 and none after the regulatory change of January 2022 (CBC News, 2022).
Case 2.2 shows that legal access began as individual, compassionate exceptions sought by patients and an advocacy organization. Such exemptions depend on ministerial discretion, and Lesson 11 describes the court cases, including Toth v. Canada (2025), in which practitioners later challenged refusals.
9.1.3 The Special Access Program, 2022
Health Canada's Special Access Program allows practitioners to request drugs not approved for sale in Canada for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable or are unavailable. Amendments made in 2013 had made restricted drugs, the category that includes psilocybin and MDMA, the only controlled substances that could not be requested in this way, so that clinical trials became the only route through which their sale could be authorized for treatment. Regulations registered on 21 December 2021 and published and in force on 5 January 2022 restored practitioners' ability to request restricted drugs through the program (Canada Gazette, 2022). The accompanying analysis cited the "breakthrough therapy" designations that the United States Food and Drug Administration had granted to MDMA for post-traumatic stress disorder and to psilocybin for treatment-resistant depression (Canada Gazette, 2022). On 1 October 2026, the Controlled Substances Regulations came into force and brought the rules for restricted drugs, formerly in Part J of the Food and Drug Regulations, into a single set of regulations (Canada Gazette, 2025); Lesson 11 explains how the program works under them.
10.1 A Time Line of the Lesson
Interactive 2.3 sets the Canadian and international events of this lesson side by side. Filter the entries by place or period, select an entry to read it, and answer the question inside the entries that have one.
Ceremony, psychiatry, prohibition and revival: Canadian and international events
Interactive 2.3 shows that Canada appears at several turning points. Saskatchewan and New Westminster were centres of therapeutic research in the 1950s, Montreal was the site of coercive experiments funded in part by two governments, Canada joined the 1971 Convention only in 1988 with a reservation for peyote, and Canadian exemptions in 2017 and 2020 reopened legal access before any psilocybin or MDMA product had been approved. International events, from the Inquisition to the DEA's scheduling of MDMA, often set the limits within which Canadian practitioners worked.
10.2 What the History Suggests for Practice
The course treats psychedelic-assisted therapy as a structured clinical process with safety, consent and legality at its centre, and much of that standard traces to this history. The five flip cards below connect each period to a practice standard.
Imagine a hypothetical interdisciplinary palliative care team in British Columbia that is considering whether to help eligible patients request psilocybin-assisted therapy through Health Canada's Special Access Program. Write a one-page briefing for the team that draws on three events from this lesson: the Saskatchewan and Hollywood Hospital research of 1953 to 1975, the Allan Memorial Institute experiments of 1957 to 1964, and the exemptions of August 2020 described in Case 2.2. For each event, state in two or three sentences what happened, with its date and source, and what it implies for the team's approach to evidence, consent or legal access. End with one question about the history of ceremonial traditions that the team should consider before it describes any service to patients or the public.
Summary
MDMA moved from psychotherapy in the late 1970s to Schedule I in the United States, despite an administrative law judge's recommendation of Schedule III. MAPS (1986) and the Heffter Research Institute (1993) supported the research that followed. Griffiths et al. (2006) revisited the question of the 1962 Good Friday Experiment with a more careful design, after Doblin had shown that the earlier study under-reported difficulties and lost its blind. The retraction of a 2002 study of MDMA neurotoxicity showed that claims of harm need the same scrutiny as claims of benefit. In Canada, exemptions in 2017 and 2020 and the Special Access Program amendments of January 2022 reopened legal access.
The final assessment that follows brings the four sections together. Lesson 3 then turns from history to pharmacology, examining how psychedelics act at receptors, how they are absorbed and eliminated, and how they interact with other medications.
Key Takeaways
- 8.1 Alexander Shulgin tried MDMA in 1976 and in 1977 gave it to the psychotherapist Leo Zeff, who used it as an adjunct to psychotherapy and introduced it to other therapists. The DEA proposed Schedule I in 1984 and placed MDMA there on an emergency basis in 1985; Administrative Law Judge Francis Young recommended Schedule III in 1986, which would have allowed medical use, but the DEA overruled him, and after a brief removal MDMA returned to Schedule I in March 1988.
- 8.2 Rick Doblin founded MAPS in 1986, in the aftermath of MDMA's scheduling, so that research on MDMA and other psychedelics could continue, and its public benefit company was renamed Lykos Therapeutics in 2024 and later Resilient Pharmaceuticals. The Heffter Research Institute, incorporated in New Mexico in 1993 with David Nichols as president, supported the 2016 studies of psilocybin-assisted therapy in people with cancer and pilot studies in addiction.
- 8.3 The Good Friday Experiment of 1962 gave psilocybin or nicotinic acid to 20 divinity students before a chapel service, and Doblin's follow-up 24 to 27 years later found that difficult experiences had been under-reported, a tranquilizer injection omitted and the blind broken. Griffiths et al. (2006) kept the central question but used individual sessions, an active comparison drug, six extra volunteers to obscure the design and ratings by community observers, and they reported significant fear in about a third of volunteers. Neither study could fully prevent participants from recognizing psilocybin's effects.
- 8.4 A 2002 study in Science reported severe dopaminergic neurotoxicity in primates given MDMA, but the authors retracted it in 2003 after finding that all but one animal had received d-methamphetamine from a mislabelled bottle. The episode shows that a single animal study establishes little about human risk until it is replicated, that the identity of a study drug must be verified, and that claims of harm deserve the same scrutiny as claims of benefit.
- 9.1 Legal access in Canada reopened through subsection 56(1) exemptions before any psilocybin or MDMA product had been approved. Two ayahuasca churches received exemptions in June 2017, subject to conditions that included health screening; four people with incurable cancer, supported by TheraPsil, received psilocybin exemptions announced on 4 August 2020, followed by training exemptions for practitioners in December 2020. Amendments in force on 5 January 2022 restored practitioners' ability to request restricted drugs such as psilocybin and MDMA through the Special Access Program.
- 10.1 Placed in sequence, the events of this lesson show Canada at several turning points: Saskatchewan and New Westminster as centres of therapeutic research in the 1950s, Montreal as the site of coercive experiments funded in part by two governments, accession to the 1971 Convention only in 1988 with a reservation for peyote, and exemptions in 2017 and 2020 that reopened legal access. International events, from the Inquisition to the DEA's scheduling of MDMA, often set the limits within which Canadian practitioners worked.
- 10.2 Each period of this history connects to a standard of practice: respect for the ceremonial origins of these medicines, attention to setting and the therapeutic relationship, claims stated with the strength of their evidence, informed consent with independent oversight, and practice only through authorized legal routes. These standards are why the course treats psychedelic-assisted therapy as a structured clinical process with safety, consent and legality at its centre.
Reflection
On 4 August 2020, it was announced that Canada's Minister of Health had granted exemptions under subsection 56(1) of the Controlled Drugs and Substances Act to four people with incurable cancer to use psilocybin for end-of-life distress, with applications supported by TheraPsil, a Victoria-based non-profit. An earlier application had been refused in March 2020. CBC News reported that 79 patients received such exemptions between August 2020 and January 2022 and that none were granted after 5 January 2022, when amendments restored practitioners' ability to request restricted drugs such as psilocybin through the Special Access Program. In the United States in 1986, the DEA placed MDMA in Schedule I although its own administrative law judge had recommended Schedule III. The course's practice standard holds that clinicians should administer or support the use of controlled psychedelics only through authorized routes: clinical trials, the Special Access Program and section 56 exemptions. In 120 to 250 words, identify one strength and one weakness of relying on case-by-case ministerial exemptions for access, and explain why the course's standard insists on authorized routes.
Minimum 20 characters required.
Question 1: What did Administrative Law Judge Francis Young recommend for MDMA in May 1986?
Question 2: What did Doblin's (1991) follow-up of the 1962 Good Friday Experiment reveal?
Question 3: Why was the 2002 study by Ricaurte and colleagues on MDMA neurotoxicity in primates retracted?
Question 4: Which of these steps in Canada's reopening of legal access came first?
Final Assessment
Bringing It All Together
This lesson followed psychedelics through four periods. Indigenous peoples used peyote, psilocybin mushrooms, ayahuasca and iboga in ceremony for centuries before clinical research, and these traditions were condemned by religious authorities, restricted by states and then harmed again by outside attention, as María Sabina's community learned after 1957. In the 1950s, Canada became a centre of psychedelic psychiatry: Osmond and Hoffer in Saskatchewan gave LSD to people with alcohol use disorder, Osmond proposed the word "psychedelic" in 1956 correspondence with Aldous Huxley and introduced it publicly in 1957, and Hollywood Hospital in New Westminster offered private LSD treatment from 1957, with case files opened until 1968.
The same period produced coercion. MKUltra funded covert drug testing, and at the Allan Memorial Institute in Montreal Ewen Cameron's depatterning, funded in part by the CIA and by Canada, harmed patients who never consented, although the Nuremberg Code of 1947 had already made voluntary consent essential. Stricter evidence standards from 1962, criminalization and the 1971 Convention ended the first research era, while reservations preserved ceremonial peyote use.
The revival began with MDMA's contested scheduling in the 1980s and the founding of MAPS and the Heffter Research Institute, and Griffiths et al. (2006) revisited the question of mystical experience with a more careful design. It also had to correct its own record, from the under-reported difficulties of the Good Friday Experiment to the retracted study of MDMA neurotoxicity. In Canada, exemptions in 2017 and 2020 and the Special Access Program amendments of 2022 reopened legal access.
Key Takeaways from this lesson
- Ceremonial use of peyote, psilocybin mushrooms, ayahuasca and iboga predates clinical research by centuries, and a 2005 radiocarbon study dated peyote specimens from Texas to about 5,700 years ago.
- Religious and state authorities suppressed several of these traditions, and outside attention, such as Wasson's 1957 article, brought tourism, blame and violence to María Sabina's community. Indigenous organizations have responded with statements and principles, including the 2020 request that decriminalization campaigns not name peyote and the eight principles of Celidwen et al. (2023), and any outside account of ceremony can be judged by who speaks, who consented, what evidence it offers and who benefits.
- Osmond and Hoffer made Saskatchewan a centre of LSD research in the 1950s, including single-session LSD treatment of alcohol use disorder, and Osmond proposed the word "psychedelic" in 1956 correspondence with Aldous Huxley and introduced it publicly in 1957.
- Hollywood Hospital's documented LSD treatment ran from 1957, with case files opened until 1968 and closure by 1975; larger figures in popular accounts are reported claims. The psycholytic model used many lower-dose sessions within psychodynamic therapy, while the psychedelic model used one or two high-dose sessions aimed at a peak experience.
- A 2012 meta-analysis of six randomized trials of LSD for alcohol use disorder found a benefit at first follow-up (odds ratio 1.96) that was no longer detectable at twelve months, and a 2022 review reads these trials differently; summing the counts gives a larger crude odds ratio of 2.30 because it ignores differences between the trials.
- MKUltra and Cameron's depatterning breached the voluntary consent required by the Nuremberg Code of 1947, and Canada's responses run from the Cooper report of 1986 and the payments of 1992 to a class action authorized in 2025.
- Drug regulation, criminalization and the 1971 Convention ended the first research era, while reservations by Canada and the United States preserved ceremonial peyote use.
- The revival combined new organizations, MAPS and the Heffter Research Institute, and more careful designs such as Griffiths et al. (2006) with corrections to the record, from the Good Friday follow-up to the Ricaurte retraction.
- Canada reopened legal access through exemptions for ayahuasca churches in 2017 and for psilocybin in 2020, and through the Special Access Program amendments of 2022.
- Read in sequence, the four periods ground the course's standards of practice: respect for ceremonial origins, attention to setting, honest statements of evidence, informed consent with oversight, and practice only through authorized routes.
Core Concepts Reviewed
Section 1: Ceremonial traditions (peyote meetings, veladas, ayahuasca churches and Bwiti), colonial suppression, harms of outside attention and Indigenous-led responses.
Section 2: Model psychosis, the coining of "psychedelic," LSD treatment of alcohol use disorder, Hollywood Hospital, psycholytic and psychedelic models, risk difference, odds ratio and meta-analysis.
Section 3: MKUltra, psychic driving and depatterning, the Nuremberg Code, ex gratia payments and the class action, drug regulation in 1962, criminalization and the 1971 Convention with its peyote reservations.
Section 4: MDMA's scheduling, MAPS and the Heffter Research Institute, the Good Friday Experiment and Griffiths et al. (2006), retraction, section 56 exemptions and the Special Access Program.
Before the final assessment, take a few minutes to connect two periods of this history to a decision that a psychedelic service in British Columbia might face today.
Reflection
This lesson covered four periods: ceremonial traditions and their suppression (for example, the burning of María Sabina's house after 1957 and the 2020 statement by Native American Church organizations asking that peyote not be named in decriminalization campaigns); mid-century Canadian psychiatry (Osmond and Hoffer's LSD treatment of alcohol use disorder from 1953, Hollywood Hospital's LSD case files from 1957 to 1968, and a 2012 meta-analysis finding a benefit at first follow-up that faded by twelve months); coercion and prohibition (Cameron's depatterning funded in part by the CIA from 1957, the Nuremberg Code of 1947, and the 1971 Convention with Canada's 1988 peyote reservation); and the revival (MDMA's scheduling in 1985 to 1988, Griffiths et al. in 2006, and Canada's psilocybin exemptions of 2020). Imagine a hypothetical health authority in British Columbia planning a psilocybin-assisted therapy service for people receiving palliative care. In 150 to 250 words, choose one episode from each of two different periods and explain what each implies for how the service should handle evidence, consent, legality or relations with Indigenous communities.
Minimum 30 characters required.
Final Knowledge Assessment
Question 1: Which two events in this lesson both took place at Red Pheasant, Saskatchewan?
Question 2: Which statement about the word "psychedelic" is accurate?
Question 3: Which comparison of the Toronto (1966) and Baltimore (1970) trials of LSD for alcohol use disorder is accurate?
Question 4: Which principle of the Nuremberg Code was breached both by the CIA's tests on unwitting subjects and by two of the 1960s LSD trials for alcohol use disorder?
Question 5: Which source gives the more reliable dates for LSD treatment at Hollywood Hospital, and why?
Question 6: Which sequence of events in MDMA's history is in the correct order?
Question 7: Worked Example 2.1 sums the counts from five trials and obtains an odds ratio of 2.30, while Krebs and Johansen (2012) report 1.96. Why do the two differ?
Question 8: Which of these is one of the four harms that Celidwen et al. (2023) attribute to the extraction and commercialization of traditional Indigenous medicines?
Question 9: Canada made its 1988 reservation for peyote under paragraph 3 of Article 32 of the 1971 Convention. Why?
Question 10: Which design feature did Griffiths et al. (2006) use that the 1962 Good Friday Experiment did not?
Question 11: Which fact most directly weakens the claim that depatterning was acceptable by the standards of its time?
Question 12: Which statement about the psilocybin exemptions announced on 4 August 2020 is accurate?
Question 13: Canada's Controlled Drugs and Substances Act lists mescaline in Schedule III "but not peyote (lophophora)." Which other fact from this lesson is consistent with that exclusion?
Question 14: According to the practice standard described in this lesson, through which routes may Canadian clinicians administer or support the use of controlled psychedelics?
Question 15: Which explanation of the end of the first research era is best supported by the sources in this lesson?
Glossary: Key Terms, People & Frameworks
📚 Reference page, available throughout the lesson
This glossary defines the terms, laws, organizations and people introduced in Lesson 2, with dates where they matter.